Week in review: Zero specs, better blink, GenSight insights
- Posted on: May 17 2019
- Leave a response
This week, a retired competitive agility dog dons prescription eyewear, botulism toxin becomes a first-line treatment for blepharospasm and GenSight’s experimental gene therapy for Leber’s neuropathy shows sustained benefits at 2 years.
Source: AAO
Posted in: Uncategorized
